Predicting early bactericidal activity using pre-clinical data for tuberculosis drugs: a platform for model-informed drug discovery and development
Eur Respir J
.
2023 Aug 31;62(2):2301108.
doi: 10.1183/13993003.01108-2023.
Print 2023 Aug.
Authors
Sophie L Stocker
1
2
3
4
,
Jan-Willem C Alffenaar
5
4
6
Affiliations
1
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
2
School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
3
Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, Sydney, Australia.
4
Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, Australia.
5
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
[email protected]
.
6
Westmead Hospital, Sydney, Australia.
PMID:
37652563
DOI:
10.1183/13993003.01108-2023
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antitubercular Agents* / therapeutic use
Humans
Tuberculosis* / drug therapy
Substances
Antitubercular Agents